These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 7868844)

  • 1. Fluvoxamine. A review of its safety profile in world-wide studies.
    Wagner W; Zaborny BA; Gray TE
    Int Clin Psychopharmacol; 1994; 9(4):223-7. PubMed ID: 7868844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
    Haffmans PM; Timmerman L; Hoogduin CA
    Int Clin Psychopharmacol; 1996 Sep; 11(3):157-64. PubMed ID: 8923094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluvoxamine: safety profile in extensive post-marketing surveillance.
    Buchberger R; Wagner W
    Pharmacopsychiatry; 2002 May; 35(3):101-8. PubMed ID: 12107854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suicidal risk during controlled clinical investigations of fluvoxamine.
    Letizia C; Kapik B; Flanders WD
    J Clin Psychiatry; 1996 Sep; 57(9):415-21. PubMed ID: 9746450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine as effective as clomipramine against symptoms of severe depression: results from a multicentre, double-blind study.
    Zohar J; Keegstra H; Barrelet L
    Hum Psychopharmacol; 2003 Mar; 18(2):113-9. PubMed ID: 12590404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fluvoxamine and clomipramine in depressed hospitalised patients: results from a randomised, double-blind study.
    Ottevanger EA
    Encephale; 1995; 21(4):317-21. PubMed ID: 7588171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluvoxamine versus imipramine and placebo: a double-blind comparison in depressed patients.
    Fabre L; Birkhimer LJ; Zaborny BA; Wong LF; Kapik BM
    Int Clin Psychopharmacol; 1996 Jun; 11(2):119-27. PubMed ID: 8803649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
    Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
    J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluvoxamine: a review of the controlled trials in depression.
    Ware MR
    J Clin Psychiatry; 1997; 58 Suppl 5():15-23. PubMed ID: 9184623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors.
    Grimsley SR; Jann MW
    Clin Pharm; 1992 Nov; 11(11):930-57. PubMed ID: 1464219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluvoxamine and mandibular dystonia.
    Chong SA
    Can J Psychiatry; 1995 Sep; 40(7):430-1. PubMed ID: 8548729
    [No Abstract]   [Full Text] [Related]  

  • 12. Fluvoxamine and tricyclic antidepressants (TCAs): how do the TCAs compare as "new" drugs with established fluvoxamine?
    Ashford JJ
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():27-31. PubMed ID: 7622820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and safety of fluvoxamine and other antidepressants.
    Westenberg HG; Sandner C
    Int J Clin Pract; 2006 Apr; 60(4):482-91. PubMed ID: 16620364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sexual dysfunction and fluvoxamine therapy.
    Waldinger MD; Olivier B
    J Clin Psychiatry; 2001 Feb; 62(2):126-7. PubMed ID: 11247099
    [No Abstract]   [Full Text] [Related]  

  • 15. Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation.
    Bondolfi G; Chautems C; Rochat B; Bertschy G; Baumann P
    Psychopharmacology (Berl); 1996 Dec; 128(4):421-5. PubMed ID: 8986013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.
    Zanardi R; Franchini L; Serretti A; Perez J; Smeraldi E
    J Clin Psychiatry; 2000 Jan; 61(1):26-9. PubMed ID: 10695642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness.
    Wilde MI; Plosker GL; Benfield P
    Drugs; 1993 Nov; 46(5):895-924. PubMed ID: 7507038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Toxicity with selective serotonin reuptake inhibitors.
    Solomons K; Gooch S; Wong A
    Am J Psychiatry; 2005 Jun; 162(6):1225. PubMed ID: 15930079
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data.
    Szegedi A; Wetzel H; Leal M; Härtter S; Hiemke C
    J Clin Psychiatry; 1996 Jun; 57(6):257-64. PubMed ID: 8666564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Milnacipran and selective serotonin reuptake inhibitors in major depression.
    Lopez-Ibor J; Guelfi JD; Pletan Y; Tournoux A; Prost JF
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():41-6. PubMed ID: 8923126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.